All In Biotech

Drug Trial Radar · NCT05438420

Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

A Phase 1B/2, Open-label Study of Q702 in Combination With Intravenous Pembrolizumab in Patients With Selected Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Feb 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Jan 12, 2023

Primary completion

Dec 30, 2027

Study completion Mar 30, 2028

Sponsor

Lead sponsor
Qurient Co., Ltd.Industry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Jun 30, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a phase 1B/2 open-label, study to determine safety and preliminary efficacy of Q702 in combination with pembrolizumab in study subjects with advanced esophageal, gastric/GEJ, hepatocellular, and cervical cancers.

Conditions

  • Esophageal Cancer
  • Gastric Cancer
  • Hepatocellular Cancer
  • Cervical Cancer

Interventions

  • Q702Drug

    The study drug Q702 will be administered once daily by mouth on Days 1 through 7, Days 15 through 21 and Days 29 through 35 of every treatment cycle.

  • PembrolizumabBiological

    Pembrolizumab will be administered using IV infusion on Day 1 of each 3-week treatment cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-related adverse events as assessed by CTCAETime frame: Up to approximately 2 years (Each Cycle is 42 Days)
  2. Tumor response using RECIST version 1.1 throughout studyTime frame: Up to approximately 2 years (Each Cycle is 42 Days)

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Southern California

    Los Angeles, California

  • Norton Cancer Institute

    Louisville, Kentucky

  • CHA Bundang Medical Center

    Seongnam-si, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.